Which has the lower trailing P/E, ALNY or HUM?

HUM has the lower trailing P/E: ALNY trades at 44.95 and HUM at 38.02. P/E is one valuation measure and does not by itself establish which business is cheaper.

Which has grown faster, ALNY or HUM?

Over the past five years, ALNY grew revenue faster — ALNY at a 47.53% CAGR versus HUM at 12.61%.

Does ALNY or HUM pay a bigger dividend?

HUM pays a dividend (0.88% yield), while ALNY has no payments in the available dividend history.

Is ALNY or HUM more profitable?

ALNY runs the higher net margin — ALNY at 16.82% versus HUM at 0.88%.

How have ALNY and HUM total returns compared?

Over the past 10 years, ALNY delivered 14.42% and HUM delivered 9.43% annualized total return. Past performance doesn't predict future results.

Alnylam Pharmaceuticals, Inc. (ALNY) vs Humana Inc. (HUM)

A side-by-side comparison of Alnylam Pharmaceuticals, Inc. and Humana Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of September 5, 2026. Differences are shown without an overall score or investment verdict.

ALNY

Alnylam Pharmaceuticals, Inc.

$35.61B

$266.11HealthcareAt close: Sep 4, 2026, 4:00 PM ET

HUM

Humana Inc.

$48.22B

$401.54HealthcareAt close: Sep 4, 2026, 4:00 PM ET

Total return — ALNY vs HUM

growth of $100 · dividends reinvested · last 10y

ALNY +266.9% (+13.9%/yr)HUM +144.8% (+9.4%/yr)ALNY compounded faster over this window

ALNY HUM

ALNY vs HUM: by the numbers

•HUM is the larger company ($48.22B vs $35.61B market cap).
•HUM trades at the lower trailing earnings multiple (38.02 vs 44.95 P/E), one valuation lens rather than an overall verdict.
•ALNY converts more revenue to profit (16.82% vs 0.88% net margin).
•ALNY grew revenue faster over the past five years (47.53% vs 12.61% CAGR).
•HUM pays a dividend (0.88% yield), while ALNY has no payments in the available dividend history.

Metrics side by side

Valuation

Metric	ALNY	HUM
P/E ratio	44.95	38.02
Forward P/E	39.61	43.87
P/S ratio	7.66	0.33
P/B ratio	27.17	2.53
EV / EBITDA	34.48	20.16
FCF yield	1.47%	N/A

Profitability

Metric	ALNY	HUM
Gross margin	79.72%	13.65%
Operating margin	20.81%	1.39%
Net margin	16.82%	0.88%
ROE	59.67%	6.65%
ROIC	24.71%	4.52%

Dividends

Metric	ALNY	HUM
Dividend yield	N/A	0.88%
Payout ratio	N/A	35.87%

Growth (annualized)

Metric	ALNY	HUM
Revenue CAGR (5Y)	47.53%	12.61%
EPS CAGR (5Y)	N/A	-17.27%
FCF CAGR (5Y)	N/A	-17.19%
Total return CAGR (5Y)	6.15%	0.31%

Frequently asked

Which has the lower trailing P/E, ALNY or HUM?: HUM has the lower trailing P/E: ALNY trades at 44.95 and HUM at 38.02. P/E is one valuation measure and does not by itself establish which business is cheaper.
Which has grown faster, ALNY or HUM?: Over the past five years, ALNY grew revenue faster — ALNY at a 47.53% CAGR versus HUM at 12.61%.
Does ALNY or HUM pay a bigger dividend?: HUM pays a dividend (0.88% yield), while ALNY has no payments in the available dividend history.
Is ALNY or HUM more profitable?: ALNY runs the higher net margin — ALNY at 16.82% versus HUM at 0.88%.
How have ALNY and HUM total returns compared?: Over the past 10 years, ALNY delivered 14.42% and HUM delivered 9.43% annualized total return. Past performance doesn't predict future results.

Go deeper

Full ALNY analysis Full HUM analysis Interactive comparison tool

Dig into the metrics

Alnylam Pharmaceuticals P/E ratio Humana P/E ratio Humana dividend yield Alnylam Pharmaceuticals ROE Humana ROE Alnylam Pharmaceuticals operating margin Humana operating margin Alnylam Pharmaceuticals revenue growth Humana revenue growth Alnylam Pharmaceuticals free cash flow Humana free cash flow

Alnylam Pharmaceuticals & Humana appear in these rankings

Fastest Revenue Growth Stocks Highest ROE Stocks Highest ROIC Stocks Highest 10-Year Total Return Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified September 5, 2026.